{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"13.4","value":"0"},{"groupId":"OG001","lowerLimit":"0","upperLimit":"28","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"CR is a disappearance of all target and non-target lesions and normalization of tumor marker level.","dispersionType":"80% Confidence Interval","groups":[{"description":"Participants received intravenous infusions of ramucirumab 9 mg/kg, gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG000","title":"Ramucirumab + Gemcitabine + Docetaxel"},{"description":"Participants received intravenous infusions of gemcitabine 900 mg/m2 on days 1, 8, and docetaxel 75 mg/m2 on day 8 of a 21-day cycle until disease progression or a criterion for discontinuation were met.","id":"OG001","title":"Gemcitabine + Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants.","reportingStatus":"POSTED","timeFrame":"Baseline Up to 6.94 months","title":"Complete Response (CR): Percentage of Participants Who Achieve CR","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}